4678 results
Keyword Tadalafil Sun Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Tadalafil Lilly
tadalafil, Erectile Dysfunction
Date of authorisation: 22/03/2017, Revision: 5, Authorised, Last updated: 17/11/2021Tadalafil Lilly Mental Disorders Sexual … Authorised tadalafil Overview This is a summary … assessment report (EPAR) for Tadalafil Lilly. It explains how the … -
List item
Human medicine European public assessment report (EPAR): Tadalafil Mylan
tadalafil, Erectile Dysfunction
Date of authorisation: 21/11/2014,
, Revision: 14, Authorised, Last updated: 30/06/2022
Tadalafil Mylan Mental Disorders Sexual … Authorised tadalafil Overview This is a summary … assessment report (EPAR) for Tadalafil Mylan. It explains how the … -
List item
Summary of opinion: Adcirca (previously Tadalafil Lilly)
tadalafil, opinion date: 16/12/2022, Positive, Last updated: 16/12/2022Adcirca (previously Tadalafil Lilly): Pending EC decision … authorisation) Adcirca tadalafil On 15 December 2022, the … Adcirca (previously Tadalafil Lilly) Adcirca (previously Tadalafil Lilly tadalafil … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cialis, tadalafil
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000452-PIP02-10-M06, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Oral suspension
Decision date: 11/09/2020, Last updated: 08/07/2021, Compliance check: XCialis Adcirca (previously Tadalafil Lilly) Adcirca Active substance … Adcirca Active substance tadalafil Therapeutic area Cardiovascular … paediatric investigation plan for tadalafil (Adcirca, Cialis), (EMEA-000452-PIP02-10-M06 … -
List item
Human medicine European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly)
tadalafil, Hypertension, Pulmonary
Date of authorisation: 01/10/2008, Revision: 15, Authorised, Last updated: 21/12/2022Adcirca (previously Tadalafil Lilly) Hypertension Vascular … Authorised tadalafil Overview This is a summary … medicine. active substance tadalafil. It is available as tablets … -
List item
Human medicine European public assessment report (EPAR): Talmanco (previously Tadalafil Generics)
tadalafil, Hypertension, Pulmonary
Date of authorisation: 09/01/2017,, Revision: 7, Authorised, Last updated: 09/06/2022
Talmanco (previously Tadalafil Generics) Respiratory Tract … Talmanco (previously Tadalafil Generics … Talmanco, INN-tadalafil 30 Churchill Place … -
List item
Human medicine European public assessment report (EPAR): Cialis
tadalafil, Erectile Dysfunction
Date of authorisation: 12/11/2002, Revision: 30, Authorised, Last updated: 11/10/2021Authorised tadalafil Overview This is a summary … containing the active substance tadalafil. It is available as tablets … active substance of Cialis, tadalafil, belongs to a group of medicines … -
List item
Human medicine European public assessment report (EPAR): Sunitinib Accord
sunitinib, Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors
Date of authorisation: 11/02/2021,
, , Revision: 1, Authorised, Last updated: 14/12/2021
Sunitinib Accord Cancer Neoplasms Neoplasms … Sunitinib Accord … EMA/18013/2021 EMEA/H/C/005419 Sunitinib Accord sunitinib) An overview of Sunitinib Accord and why it is authorised … -
List item
Human medicine European public assessment report (EPAR): Sutent
sunitinib, Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors
Date of authorisation: 19/07/2006, Revision: 39, Authorised, Last updated: 13/08/2021sunitinib … Sutent; INN-sunitinib 30 Churchill Place … for the public Sutent sunitinib This is a summary of the … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Sutent, sunitinib
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-000342-PIP01-08-M07, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard
Decision date: 07/05/2018, Last updated: 27/11/2018, Compliance check: V, 29/06/2018name Sutent Active substance sunitinib Therapeutic area Oncology … Sutent Sutent sunitinib sunitinib sunitinib … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Macitentan, tadalafil
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-001961-PIP01-16, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 09/09/2016, Last updated: 27/10/2016, Compliance check: XKey facts Macitentan tadalafil Cardiovascular diseasesP/0243/2016EMEA-001961-PIP01-16 … specific waiver for macitentan / tadalafil (EMEA-001961-PIP01-16) PDF … specific waiver for macitentan / tadalafil (EMEA-001961-PIP01-16 … -
List item
Withdrawn application: Sutent
sunitinib, date of withdrawal: 26/06/2018, Post-authorisation, Last updated: 17/08/2018authorisation for Sutent (sunitinib) On 26 June 2018, Pfizer … contains the active substance sunitinib. Further information on … active substance in Sutent, sunitinib, is a protein kinase inhibitor … -
List item
Withdrawn application: Docetaxel SUN
docetaxel, date of withdrawal: 06/06/2016, Initial authorisation, Last updated: 29/09/2016Docetaxel SUN: Withdrawn application … application for Docetaxel Sun (docetaxel) On 6 June … docetaxel) On 6 June 2016, Sun Pharmaceutical Industries … -
List item
Withdrawn application: Topotecan SUN
topotecan, date of withdrawal: 03/01/2011, Initial authorisation, Last updated: 23/02/2011Topotecan SUN: Withdrawn application … Topotecan SUN: Withdrawal of the marketing … application for Topotecan SUN (topotecan) On 3 January … -
List item
Withdrawn application: Repaglinide Sun
repaglinide, date of withdrawal: 25/03/2010, Initial authorisation, Last updated: 15/05/2010Repaglinide Sun: Withdrawn application … Repaglinide Sun: Withdrawal of the marketing … application for Repaglinide Sun (repaglinide) On 23 March … -
List item
Withdrawn application: Doxorubicin SUN
doxorubicin, date of withdrawal: 20/07/2011, Initial authorisation, Last updated: 26/09/2011Doxorubicin SUN: Withdrawn application … application for Doxorubicin SUN (doxorubicin) On 20 Jul … doxorubicin) On 20 Jul 2011, Sun Pharmaceutical Industries … -
List item
Summary of opinion: Sitagliptin / Metformin hydrochloride Sun (new)
sitagliptin, metformin hydrochloride, opinion date: 26/01/2023, Positive, Last updated: 27/01/2023Metformin hydrochloride Sun: Pending EC decision … Metformin hydrochloride Sun … Sitagliptin/Metformin hydrochloride Sun sitagliptin / metformin … -
List item
Human medicine European public assessment report (EPAR): Sunlenca
Lenacapavir sodium, HIV Infections
Date of authorisation: 17/08/2022,, Authorised, Last updated: 25/08/2022
Sunlenca Blood-Borne Infections Communicable … Sunlenca … EMA/624383/2022 EMEA/H/C/005638 Sunlenca (lenacapavir) An overview … -
List item
Human medicine European public assessment report (EPAR): Teriparatide Sun
teriparatide, Osteoporosis; Osteoporosis, Postmenopausal
Date of authorisation: 18/11/2022, Authorised, Last updated: 12/12/2022Teriparatide Sun Bone Diseases, Metabolic Bone … teriparatide Overview Teriparatide Sun is a medicine used to treat … steroid). Teriparatide Sun is a ‘ A medicine that … -
List item
Human medicine European public assessment report (EPAR): Sunosi
solriamfetol hydrochloride, Narcolepsy; Sleep Apnea, Obstructive
Date of authorisation: 16/01/2020,, Revision: 7, Authorised, Last updated: 14/12/2022
Sunosi Nervous System Diseases Sleep … orised solriamfetol Overview Sunosi is a medicine used to improve … disturbed night-time sleep. Sunosi is used in patients with … -
List item
Human medicine European public assessment report (EPAR): Levetiracetam Sun
levetiracetam, Epilepsy
Date of authorisation: 14/12/2011,, Revision: 17, Authorised, Last updated: 24/06/2022
Levetiracetam Sun Nervous System Diseases Central … Levetiracetam Sun … EMEA/H/C/002051 Levetiracetam Sun (levetiracetam) An overview … -
List item
Human medicine European public assessment report (EPAR): Temozolomide Sun
temozolomide, Glioma; Glioblastoma
Date of authorisation: 13/07/2011,, Revision: 19, Authorised, Last updated: 17/03/2022
Temozolomide Sun Cancer Neuroectodermal … Temozolomide Sun … Temozolomide SUN, INN-temozolomide … -
List item
Human medicine European public assessment report (EPAR): Bortezomib Sun
bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016,, Revision: 12, Authorised, Last updated: 09/09/2021
Bortezomib Sun Hemostatic Disorders Vascular … Bortezomib Sun … Bortezomib SUN, INN-bortezomib 30 … -
List item
Human medicine European public assessment report (EPAR): Capecitabine SUN
capecitabine, Stomach Neoplasms; Breast Neoplasms; Colonic Neoplasms; Colorectal Neoplasms
Date of authorisation: 21/06/2013,, Revision: 3, Withdrawn, Last updated: 22/12/2016
Capecitabine SUN Stomach Neoplasms Breast … Capecitabine SUN … statement Capecitabine SUN Withdrawal of the marketing … -
List item
Human medicine European public assessment report (EPAR): Ertapenem SUN
ertapenem sodium, Bacterial Infections
Date of authorisation: 15/07/2022,, Authorised, Last updated: 21/11/2022
Ertapenem SUN Bacterial Infections and … ertapenem Overview Ertapenem SUN is an antibiotic. It is used … diabetes patients. Ertapenem SUN is also used in adults to …